KIT and systemic mastocytosis: This confirms a recent report from the Mayo Clinic registry on 22 cladribine-treated AdvSM patients indicating a diagnosis of an AHN (in addition to older age and absence of KIT D816V) as adverse prognostic markers for survival and is also in line with a previous publication on the poor prognostic impact of eosinophilia in SM [18, 37].